These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2217853)

  • 21. Surrogate markers of small fiber damage in human diabetic neuropathy.
    Quattrini C; Tavakoli M; Jeziorska M; Kallinikos P; Tesfaye S; Finnigan J; Marshall A; Boulton AJ; Efron N; Malik RA
    Diabetes; 2007 Aug; 56(8):2148-54. PubMed ID: 17513704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevalence of peripheral neuropathy in newly diagnosed patients with non-insulin-dependent diabetes mellitus.
    Weerasuriya N; Siribaddana S; Wijeweera I; Dissanayeka A; Wijesekera J; Fernando DJ
    Ceylon Med J; 1998 Mar; 43(1):19-21. PubMed ID: 9624839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular risk factors and diabetic neuropathy.
    Sone H; Mizuno S; Yamada N
    N Engl J Med; 2005 May; 352(18):1925-7; author reply 1925-7. PubMed ID: 15877321
    [No Abstract]   [Full Text] [Related]  

  • 24. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus.
    González-Clemente JM; Mauricio D; Richart C; Broch M; Caixàs A; Megia A; Giménez-Palop O; Simón I; Martínez-Riquelme A; Giménez-Pérez G; Vendrell J
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):525-9. PubMed ID: 16268804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects.
    Enck P; Rathmann W; Spiekermann M; Czerner D; Tschöpe D; Ziegler D; Strohmeyer G; Gries FA
    Z Gastroenterol; 1994 Nov; 32(11):637-41. PubMed ID: 7886972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.
    Diabetes; 1988 Apr; 37(4):476-81. PubMed ID: 2897940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Autonomic neuropathy in diabetes mellitus: significance in the clinic and general practice].
    Nusser J; Landgraf R
    Internist (Berl); 1990 Mar; 31(3):198-207. PubMed ID: 2160443
    [No Abstract]   [Full Text] [Related]  

  • 28. [Risk factors involved in symmetrical distal diabetic neuropathy].
    Gómez-Viera N; Soto-Lavastida A; Roselló-Silva H; Gómez de Molina-Iglesias M
    Rev Neurol; 2001 May 1-15; 32(9):806-12. PubMed ID: 11424028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Disorders of sorbitol and myoinositol metabolism and the activity of sodium, potassium ATPase in the pathogenesis of peripheral neuropathy in patients with diabetes mellitus].
    Mosiewicz J; Grzywa M
    Pol Tyg Lek; 1992 Jan 6-13; 47(1-2):56-8. PubMed ID: 1329048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes.
    Antonelli A; Tuomi T; Nannipieri M; Fallahi P; Nesti C; Okamoto H; Groop L; Ferrannini E
    Diabetologia; 2002 Sep; 45(9):1298-306. PubMed ID: 12242463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy.
    Zhuang HX; Wuarin L; Fei ZJ; Ishii DN
    J Pharmacol Exp Ther; 1997 Oct; 283(1):366-74. PubMed ID: 9336345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Electrophysiologic changes in peripheral nerves in patients with 2 acetylation types of diabetes mellitus].
    Kopeć A; Rowińska-Marcińska K; Stryjek-Kamińska D; Malczewski B
    Neurol Neurochir Pol; 1986; 20(6):547-52. PubMed ID: 3600972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement component 3 (C3) genetics and diabetes mellitus.
    Krantz S; Stelter F; Lober M; Gromoll B
    Biomed Biochim Acta; 1990; 49(12):1237-41. PubMed ID: 2097995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diabetic neuropathy--risk factors and pathogenesis].
    Takasu T
    Nihon Rinsho; 1997 Oct; 55 Suppl():837-47. PubMed ID: 9392206
    [No Abstract]   [Full Text] [Related]  

  • 35. Early vascular risk factor modification in type 1 diabetes.
    Perkins BA; Bril V
    N Engl J Med; 2005 Jan; 352(4):408-9. PubMed ID: 15673807
    [No Abstract]   [Full Text] [Related]  

  • 36. Acetylator phenotypes in diabetes mellitus.
    Stryjek-Kamińska D; Malczewski B; Kopeć A; Rowińska-Marcińska K
    Acta Diabetol Lat; 1988; 25(1):41-8. PubMed ID: 3407376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of diabetic neuropathy.
    Younger DS; Bronfin L
    Semin Neurol; 1996 Jun; 16(2):107-13. PubMed ID: 8987123
    [No Abstract]   [Full Text] [Related]  

  • 38. [Antitubercular agents: pharmacogenetic factors in the development of adverse effects].
    Ligueros M; Saavedra H; Neira S; Cruz-Coke R; Saavedra A; Kramer V; Gelman M; Nuñez A; Prieto JC
    Rev Med Chil; 1990 Jul; 118(7):727-35. PubMed ID: 2131519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sports medicine for the diabetic athlete.
    Morgado A; Schneider SH
    N J Med; 1991 Sep; 88(9):651-4. PubMed ID: 1745421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acetylation phenotype in diabetes mellitus].
    Stryjek-Kamińska D; Malczewski B; Kopeć A; Rowińska-Marcinska K; Czyzyk A
    Pol Arch Med Wewn; 1987 Aug; 78(2):89-96. PubMed ID: 3271290
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.